Body weight change in women receiving adjuvant chemotherapy for breast cancer: A French prospective study

Abstract While obesity increases colorectal cancer incidence, there are inconsistent results in the prognostic role of obesity or body weight change on survival. This study investigated the prognostic impact of body weight and weight change in stage III or high risk stage II colon cancer patients. We used data from patients enrolled in the phase III AVANT trial. The AVANT trial investigated the efficacy of adding bevacizumab to standard adjuvant chemotherapy (FOFOX or XELOX). Weight change during the first 6 months of adjuvant chemotherapy was measured. Cox proportional hazard model was used to assess the prognostic influence of body weight and weight change. Among 3451 intention-to-treat population, body weight and weight change was measured in 3449 (99.9%) and 2455 (71.1%) patients, respectively. Among 2455 patients, 651 (26.5%) had weight gain over 5 kg and 179 (7.3%) had weight loss over 5 kg. Weight gain was more frequently observed in Asian and male. Neither baseline BMI nor weight change affected recurrence or survival in the Cox proportional hazard model.

Download Full-text

Association of long-term body weight variability with dementia: a prospective study

The Journals of Gerontology Series A ◽

10.1093/gerona/glab372 ◽

2021 ◽

Author(s):

Hui Chen ◽

Tianjing Zhou ◽

Jie Guo ◽

John S Ji ◽

Liyan Huang ◽

...

Keyword(s):

Body Weight ◽

Prospective Study ◽

Weight Change ◽

The Body ◽

Body Weight Change ◽

Cox Proportional Hazard ◽

Incident Dementia ◽

A Prospective Study

Abstract Background Body weight variability (BWV) refers to intraindividual weight loss and gain over a period. The association of long-term BWV with dementia remains unclear and whether this association is beyond body weight change is undetermined. Methods In the Health and Retirement Study (HRS), a total of 5,547 dementia-free participants (56.7% women; mean [SD] age, 71.1 [3.2] years) at baseline (2008) were followed up to 8 years (mean=6.8 years) to detect incident dementia. Body weight was self-reported biennially from 1992-2008. BWV was measured as the coefficient of variation utilizing the body weight reported 9 times across 16 years before baseline. Cox proportional hazard model was used to estimate the hazard ratio (HR) and 95% confidence interval (CI). Results Among the 5,547 participants, a total of 427 incident dementia cases were identified during follow-up. Greater long-term BWV was significantly associated with a higher risk of dementia (HR comparing extreme quartiles: 2.01, 95% CI: 1.48-2.72; HR of each SD increment: 1.21, 95% CI: 1.10-1.32; P-trend<0.001) independent of mean body weight and body weight change. This significant association was even observed for BWV estimated approximately 15 years preceding dementia diagnosis (HR of each SD increment: 1.13, 95% CI: 1.03-1.23) and was more pronounced for that closer to diagnosis. Conclusions Our prospective study suggested that greater BWV may be a novel risk factor for dementia.

Download Full-text

Additional effect of weekly L-arginine injection on body weight change in liraglutide treatment patients

10.32581/jkifm.2020.3.1.24 ◽

2020 ◽

Vol 3 (1) ◽

pp. 24-30

Author(s):

Eun-Sub Lee ◽

Jung-Min Choi ◽

Nam-Seok Joo

Keyword(s):

Body Weight ◽

Weight Change ◽

Body Weight Change

Download Full-text

Prospective study of hair recovery after (neo)adjuvant chemotherapy with scalp cooling in Japanese breast cancer patients

Supportive Care in Cancer ◽

10.1007/s00520-021-06168-y ◽

2021 ◽

Author(s):

Shozo Ohsumi ◽

Sachiko Kiyoto ◽

Mina Takahashi ◽

Seiki Takashima ◽

Kenjiro Aogi ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Prospective Study ◽

Cancer Patients ◽

Scalp Cooling ◽

Breast Cancer Patients ◽

Chemotherapy Infusion ◽

Group A ◽

Neo Adjuvant Chemotherapy ◽

Group B

Abstract Purpose Scalp cooling during chemotherapy infusion to mitigate alopecia for breast cancer patients is becoming widespread; however, studies regarding hair recovery after chemotherapy with scalp cooling are limited. We conducted a prospective study of hair recovery after chemotherapy with scalp cooling. Patients and methods One hundred and seventeen Japanese female breast cancer patients who completed planned (neo)adjuvant chemotherapy using the Paxman Scalp Cooling System for alopecia prevention were evaluated for alopecia prevention in our prospective study. We evaluated their hair recovery 1, 4, 7, 10, and 13 months after chemotherapy. Primary outcomes were grades of alopecia judged by two investigators (objective grades) and patients’ answers to the questionnaire regarding the use of a wig or hat (subjective grades). Results Of 117 patients, 75 completed scalp cooling during the planned chemotherapy cycles (Group A), but 42 discontinued it mostly after the first cycle (Group B). Objective and subjective grades were significantly better in Group A than in Group B throughout 1 year, and at 4 and 7 months after chemotherapy. When we restricted patients to those with objective Grade 3 (hair loss of > 50%) at 1 month, Group A exhibited slightly faster hair recovery based on the objective grades than Group B. There was less persistent alopecia in Group A than in Group B. Conclusions Scalp cooling during chemotherapy infusion for Japanese breast cancer patients increased the rate of hair recovery and had preventive effects against persistent alopecia.

Download Full-text